Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Morphotek Launches ADC Services Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Morphotek Launches ADC Services Business

Aligns antibody engineering and clinical development assets into a client-focused ADC business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Morphotek, Inc., a subsidiary of Eisai Inc., has launched its Antibody Drug Conjugate (ADC) Services business based on its REsidue-SPEcific Conjugation Technology (RESPECT) and eribulin-linker toxin platforms. RESPECT is a site-specific conjugation technology that targets select amino acid residues as a way of producing investigational homogeneous ADCs with defined drug-to-antibody ratios. The platform allows for site-specific conjugation of a single cytotoxic payload or two payloads with different mechanisms of action. The platform employs eribulin as one of the cytotoxic payloads along with a proprietary high-throughput screening system that can evaluate multiple ADC products simultaneously for client-desired biophysical properties and target-specific binding.  
 
As part of its services, the eribulin-linker payload is offered as an option to develop investigational ADCs using traditional bioconjugation for companies interested in developing next-generation formats of their own antibodies.
 
“Decades of expertise in antibody engineering and clinical development of biologics-based therapies, along with preclinical studies showing the potential of our new ADC formats, has enabled us to align these assets into a client-focused ADC business offering end-to-end services,” said Nicholas Nicolaides, president and chief executive officer of Morphotek.  “We believe this new service provides an opportunity to build a win-win strategy by increasing internal value through leveraging our proprietary platforms and development know-how, and customer value by developing ADCs to their strategic targets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics